Atlas Trials

Bruton's Tyrosine Kinase Inhibitor Ibrutinib as Maintenance Treatment in Elderly Patients With Primary CNS Lymphoma

Clinical trial NCT02623010 · UNKNOWN

Trial details

NCT number
NCT02623010
Sponsor
Rabin Medical Center
Status
UNKNOWN
Phase
Phase 2
Study type
INTERVENTIONAL
Central Nervous System Lymphoma
Start date
2016-10-01
Primary completion
2023-12-01
Enrollment
30

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.